Please assess the completion status of the following clinical trial:

Trial Title: Assessment of INS1007 in Participants With Non-Cystic Fibrosis Bronchiectasis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Clinical history consistent with NCFBE (cough, chronic sputum production and/or recurrent respiratory infections)~2. Are current sputum producers with a history of chronic expectoration and able to provide a sputum sample during Screening~3. Have at least 2 documented pulmonary exacerbations in the past 12 months before Screening~Exclusion Criteria:~1. Have a primary diagnosis of chronic obstructive pulmonary disease (COPD) or asthma~2. Have bronchiectasis due to cystic fibrosis (CF), hypogammaglobulinemia, common variable immunodeficiency, or alpha1-antitrypsin deficiency~3. Are current smokers~4. Are currently being treated for a nontuberculous mycobacterial lung infection, allergic bronchopulmonary aspergillosis, or tuberculosis~5. Have any acute infections, (including respiratory infections)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 85 Years
- Healthy Volunteers: f

Study Arms:
- Brensocatib 10 mg (Type: EXPERIMENTAL): Participants received brensocatib 10 mg once daily (QD) before breakfast, for 24 weeks.
- Brensocatib 25 mg (Type: EXPERIMENTAL): Participants received brensocatib 25 mg QD before breakfast, for 24 weeks.
- Placebo (Type: PLACEBO_COMPARATOR): Participants received the matching placebo QD before breakfast, for 24 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).